Why CRISPR Therapeutics (CRSP) Soared on Friday?
We recently published a list of Shares of 10 Firms Soar on Friday. In this article, we are going to take a look at where ...
Zacks.com on MSN15h
CRSP Stock Rises 25% in a Week: Time to Buy, Hold or Sell?
The rise in CRISPR Therapeutics' share price can be attributed to the better-than-expected Q4 results and a rating upgrade by a well-established financial services firm.
Citi Sticks to Their Buy Rating for Crispr Therapeutics AG (CRSP)
Citi analyst Yigal Nochomovitz maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report) today and set a price target of ...
CRISPR Therapeutics (CRSP) Expected to Announce Quarterly Earnings on Wednesday
CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) will likely be announcing its earnings results before the market opens on ...
Crispr Therapeutics price target lowered to $82 from $89 at Citi
Citi analyst Yigal Nochomovitz lowered the firm’s price target on Crispr Therapeutics (CRSP) to $82 from $89 and keeps a Buy rating on the ...
Fintel on MSN4d
Evercore ISI Group Upgrades CRISPR Therapeutics (CRSP)
Fintel reports that on February 14, 2025, Evercore ISI Group upgraded their outlook for CRISPR Therapeutics (NasdaqGM:CRSP) ...
Crispr Therapeutics Q4 Earnings Review: Ignore The Lack Of Revenues, Buy The Future
Crispr Therapeutics AG has revenue declines but holds strong financials. Promising Sickle Cell therapy & 2025 data readouts ...
Brokers Set Expectations for CRSP Q1 Earnings
Brookline Capital Management issued their Q1 2025 earnings estimates for CRISPR Therapeutics in a research report issued on ...
CRISPR upped to outperform by Evercore on upcoming data
Evercore ISI has upgraded CRISPR (CRSP) to outperform from in line, citing upcoming data catalysts. Read more here.